Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
|Articles|September 16, 2008
- October15 2004
- Volume 11
- Issue 19
Online Brokers Rated
Author(s)Online Brokers Rated
Advertisement
Kiplinger's Personal
Finance
A recent issue of rated online brokers on a numberof criteria, from brokerage fees tocustomer service. The rankings were alsosplit into two lists: one for investors with$50,000 to invest and another for thosewith $500,000. Topping the rankings forsmall investors was Muriel Siebert &Co, which also came in second on thelarge-investor list. Fidelity Brokerage ledthe list for large investors, but slipped tofourth in the ratings for small investors,mostly due to steep costs for those withless cash. Far down on both lists wereAmeritrade and Charles Schwab; Ameritradewas downgraded based on customerservice, and Schwab scored lowdue to its fee structure.
Articles in this issue
about 18 years ago
Question Your Ideal Investment Optionabout 18 years ago
Determine when a Roth IRA Makes Senseabout 18 years ago
Ponder the Privatized Social Security Issueabout 18 years ago
Accelerate Retirement Savings with a 412(i)about 18 years ago
Replace Malpractice Fiction with Factabout 18 years ago
Expand Your Insurance Protection Planabout 18 years ago
Save More with College Rewards Programsabout 18 years ago
Select a Team Worthy of the Super Bowlabout 18 years ago
Recover Taxes from a Natural Disasterabout 18 years ago
Strengthen Your Retirement with CharityAdvertisement
Related to this article
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women
5